Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | TK1 | P04183 | 6/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TK2 | O00142 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3072181 | 0.90 | LMNA (0.46) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL3072158 | 0.90 | LMNA (0.54) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL3065258 | 0.88 | TK1 (0.43) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL3076872 | 0.88 | TK1 (0.54) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL3066249 | 0.81 | TK1 (0.51) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL3071137 | 0.81 | TK1 (0.43) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL3087366 | 0.81 | LMNA (0.57) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL5983818 | 0.80 | TK1 (0.67) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL1172396 | 0.80 | TK1 (0.67) | LMNASMN1; SMN2ALOX12ADRA1ATK1 | |
| SCHEMBL3066258 | 0.80 | TK1 (0.52) | LMNASMN1; SMN2ALOX12ADRA1ATK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2054406-B1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESPROTECT GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-8492537-B2 | Nucleosides for suppressing or reducing the development of resistance in cytostatic therapy | RESPROTECT GMBH (DE) | 2013-07-23 | — | — | US | disclosed |
| US-20100227834-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | RESprotech GmbH (DE) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227834-A1 | NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY | TYMP, ENTPD5, NTPCR | LMNA 1868/4885SMN1; SMN2 1379/4885ALOX12 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.